A Phase I Study of the NovoTTF-200M and Novo TTF-200A Systems for the Treatment of Refractory Spinal Metastasis

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT06906900
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Spinal Metastasis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • TTF-200M and TTF-200A systems — DEVICE
    Participants will receive treatment with NovoTTF-200M or NovoTTF-200A and treatment will continue as long as the doctor thinks it is in the participant's best interest.

Study Details

This clinical research study is to learn about the safety of the NovoTTF-200M and Novo TTF-200A Systems, when used either alone or in combination with standard therapy, in patients with tumors that did not respond to treatment.

Key Dates

Start date
Aug 18, 2025
Status verified
Apr 2026
Primary completion
Feb 17, 2027
Completion
Feb 17, 2029

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment with 150 KHZ (NovoTTF-200M) or 200KHZ (NovoTTF-200A)

Primary Outcome Measure

Safety and Adverse Events (AEs) [ Time Frame: Through study completion; an average of 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
The University of Texas M. D. Anderson Cancer CenterHoustonTexas77030
Claudio Tatsui, MD
[email protected]
713-563-8710
Claudio Tatsui, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

By research site
The University of Texas M. D. Anderson Cancer Center· Houston, TX

Related Studies